CDC Logo Skip Top Nav
 CDC Home PageSearch the CDCHealth Topics A though Z
Skip
Division of Tuberculosis Elimination
About DTBE Upcoming Events Site Map CDC en Espanol Contact Us
 
Skip the Contents menu

Contents

Skip the Resources menu

Resources



U.S. Department of Health and Human Services
 
 

Guide for Primary Health Care Providers: Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection 2005

Return to Table of Contents

Introduction

Latent tuberculosis infection (LTBI) is infection with Mycobacterium tuberculosis organisms (tubercle bacilli) without signs and symptoms nor radiographic or bacteriologic evidence of tuberculosis (TB) disease. When small droplet nuclei containing the tubercle bacilli reach the alveoli, they are engulfed by macrophages and usually destroyed. However, when a number survive and multiply, they can cause LTBI.

Approximately one third of the world’s population is infected with M. tuberculosis. In the United States, it is estimated that 9–14 million people have LTBI. Without treatment, approximately 5–10% will progress to TB disease at some point in their lifetime. Identifying and treating those at highest risk for TB disease will help us move toward elimination of the disease. Primary care providers play a key role in achieving the goal of TB elimination because of their access to high-risk populations. 

The Centers for Disease Control and Prevention (CDC) and the American Thoracic Society (ATS) published guidelines in the June 9, 2000 issue of Morbidity and Mortality Weekly Report (MMWR), entitled Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. In addition, updates to the 2000 guidelines have been published. Major changes from prior recommendations fall into three categories: testing for LTBI, treatment of LTBI, and clinical monitoring (see Table 1). 

Terminology used in the guidelines also reflects a change. The commonly used terms “preventive therapy” and “chemoprophylaxis” have been replaced with “treatment of latent TB infection (LTBI).”  This more accurately describes the use of a treatment regimen to prevent the development of TB disease in persons with LTBI (see Table 2).


This document is not meant to be used as a substitute for the guidelines, but rather as a ready and useful reference that highlights the main points of those guidelines.



Last Reviewed: 05/18/2008
Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

 

 
Back to Top of Page


If you would like to order any of the DTBE publications please visit the online order form.

You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format.  Download the Adobe Acrobat™ Reader.

If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available.

Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348
E-mail: cdcinfo@cdc.gov


Skip Bottom Nav Home | Site Map | Contact Us
Accessibility | Privacy Policy Notice | FOIA | USA.gov
CDC Home | Search | Health Topics A-Z

Centers for Disease Control & Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to: CDCINFO@cdc.gov